White Paper
Vial Packaging for the Biologics Market: Trends, Requirements, and Solutions
As biologics reshape the pharmaceutical landscape — projected to reach $881 billion in sales by 2030 — their structural complexity demands a new standard for primary packaging. This report examines the trends, functional requirements, and advanced stopper technologies defining vial packaging for the biologics market today.
Status
Published
Format
White Paper
Language
English
Access
Registration Required
Resource Overview
What's Inside This Report
- Understand why 94% of biologics on the US market are delivered by injection and why vials remain the dominant packaging format
- Learn how structural sensitivity, drug–container interactions, and high product value create unique packaging requirements for biologics
- Explore the core functional attributes of rubber stoppers — including container closure integrity, self-sealing, permeability control, penetrability, fragmentation, and extractables & leachables (E&L)
- Discover how evolving regulations — including EU GMP Annex 1 and USP <382> — are raising the bar for packaging component performance and functionality testing
- See how OmniFlex® coated stoppers are engineered to address biologic-specific challenges, from the FM457 elastomer core to full-surface fluoropolymer coating
- Learn how Datwyler's FirstLine® manufacturing achieves bioburden and endotoxin levels significantly below standard industry benchmarks
- Understand lyophilisation-specific stopper design requirements and how OmniFlex addresses freeze-drying challenges without sticking or leaching
- Explore how StarterPack™ kits accelerate early-stage development with commercial-grade components ready for R&D use
Access This Resource
Download the White Paper
Continue to access the full resource.
Access the White Paper
Quick access in under 30 seconds.